HYDERABAD, Jan 30 (Reuters) - Indian biopharma company Biocon (BION.NS), opens new tab reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which ...

Less than a year after buying out the biosimilar franchise of Viatris, Biocon has received a complete response letter from the FDA for its biosimilar version of insulin aspart. The agency's letter ...

An India-headquartered global biopharmaceutical company is making a big bet on the Garden State. Biocon Ltd. focuses on enhancing affordable access to complex therapies for chronic conditions, such as ...

At around 10:42 a.m., Biocon shares were up 1.51 per cent, or Rs 3.6, at Rs 242.05 apiece on BSE. The market capitalisation ...

According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were not known ...

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and ...

Biocon has named Peter Bains its next CEO as the company looks to expand its presence in North America and beyond. As part of the move, which became effective Monday, Bains will step down from ...

Profit rises 71% YoY to Rs 144 crore Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs ...

Biocon is preparing to enter the fast-growing market for GLP-1 receptor agonists, a class of drugs used to treat diabetes and obesity that includes blockbusters such as Ozempic and Mounjaro, as the ...

Mumbai: Biocon has announced plans to fully merge Biocon Biologics Limited (BBL) into the parent company by making it a wholly owned subsidiary. To achieve this, Biocon will acquire the minority ...

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd.

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...